Edwards Lifesciences (NYSE:EW) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Edwards Lifesciences from “hold” to “buy,” joining a broader positive analyst consensus. The stock has a “Moderate Buy” consensus rating and an average price target of $100.27.
• Edwards reported quarterly EPS of $0.78, beating estimates of $0.74, while revenue reached $1.74 billion and rose 13.6% year over year. Management issued fiscal 2026 EPS guidance of $2.95 to $3.05.
• The stock opened at $86.52, with a 12-month range of $72.67 to $96.29 and a market capitalization of about $49.82 billion. Institutional investors own approximately 79.46% of the company, while insiders sold 5,045 shares worth $451,596 over the past 90 days.

Edwards Lifesciences (NYSE:EW - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Other equities research analysts have also issued reports about the company. Citigroup reissued a "buy" rating on shares of Edwards Lifesciences in a research report on Monday, October 5th. BTIG Research restated a "buy" rating and set a $110.00 price objective on shares of Edwards Lifesciences in a research note on Friday, September 11th. Evercore reaffirmed an "outperform" rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Leerink Partners upgraded shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Finally, Royal Bank Of Canada upped their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $100.27.

Edwards Lifesciences Stock Performance

NYSE EW opened at $86.52 on Friday. The company has a market cap of $49.82 billion, a P/E ratio of 31.35, a PEG ratio of 2.31 and a beta of 0.87. The company has a fifty day simple moving average of $88.44 and a 200 day simple moving average of $86.33. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12-month low of $72.67 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm's revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts predict that Edwards Lifesciences will post 3.00 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the business's stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president directly owned 17,984 shares in the company, valued at $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $85.65, for a total transaction of $53,017.35. Following the transaction, the vice president directly owned 40,034 shares of the company's stock, valued at $3,428,912.10. This represents a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 5,045 shares of company stock worth $451,596. Insiders own 0.31% of the company's stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently bought and sold shares of EW. Kintegral Advisory LLC increased its position in Edwards Lifesciences by 0.6% in the third quarter. Kintegral Advisory LLC now owns 63,868 shares of the medical research company's stock worth $5,513,000 after buying an additional 361 shares during the last quarter. North Capital Inc. raised its stake in shares of Edwards Lifesciences by 10.4% in the third quarter. North Capital Inc. now owns 5,837 shares of the medical research company's stock valued at $498,000 after buying an additional 551 shares during the period. V Square Quantitative Management LLC lifted its position in shares of Edwards Lifesciences by 6.0% during the 3rd quarter. V Square Quantitative Management LLC now owns 14,865 shares of the medical research company's stock valued at $1,283,000 after buying an additional 845 shares during the last quarter. Comprehensive Financial Consultants Institutional Inc. lifted its position in shares of Edwards Lifesciences by 0.8% during the 3rd quarter. Comprehensive Financial Consultants Institutional Inc. now owns 34,684 shares of the medical research company's stock valued at $2,994,000 after buying an additional 273 shares during the last quarter. Finally, AdvisorNet Financial Inc lifted its position in shares of Edwards Lifesciences by 42.3% during the 3rd quarter. AdvisorNet Financial Inc now owns 2,393 shares of the medical research company's stock valued at $207,000 after buying an additional 711 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.